en.Wedoany.com Reported - Claude's parent company has started buying "pharmaceutical brains." Anthropic has acquired AI biotech startup Coefficient Bio for nearly $400 million, marking the company's first publicly disclosed M&A transaction in the biotechnology sector.

According to foreign media reports, Coefficient Bio's core capability is using AI models to predict protein structures and molecular interactions, accelerating lead compound screening in drug discovery. The company was previously in an early stage, with no pipeline having entered clinical trials.

Anthropic directly competes with OpenAI and Google with its Claude series of large models. The intention behind this acquisition is to integrate Coefficient Bio's proprietary datasets and biological modeling capabilities into Anthropic's underlying architecture, equipping Claude with biocomputing capabilities. In other words, Anthropic is not buying a pharmaceutical company; it is buying the capability "to make models understand proteins." [Editor's Note] In the AI drug discovery field, companies like Recursion (which received investment from NVIDIA), Insilico Medicine, and XtalPi all employ similar technological approaches.

The acquisition amount of nearly $400 million is considered a medium-sized transaction in the AI biotechnology field. For reference, NVIDIA invested $50 million in Recursion in 2023, and in 2024, Google's Isomorphic Labs established strategic partnerships with Lilly and Novartis without involving acquisitions. The amount and method (full acquisition rather than investment) of Anthropic's move indicate a preference for technological integration over financial returns.

Following the completion of the transaction, the Coefficient Bio team will be integrated into Anthropic. Neither party disclosed specific integration plans or whether Coefficient Bio's existing technology will be retained as an independent product.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com